Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with tuberculosis diagnosis, HIV positive.~* Agreement to avoid not allowed drugs during the trial, agreement to participate in the study (informed consent)~Exclusion Criteria:~* Active liver disease~* Pregnancy or breast feeding~* CD4 counts \>350

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EFAVIRENZ 800mg (Type: EXPERIMENTAL): Efavirenz 800 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin
- EFAVIRENZ 600mg (Type: ACTIVE_COMPARATOR): Efavirenz 600 mg (tablet) PO QD during 5 months associated with two nucleoside analogs during tuberculosis therapy with rifampicin

Based on this trial design, predict the completion outcome and termination type (if applicable).